Intelligent Investor

BresaGen Limited (ASX: BGN) - Announcements

DELISTED - Current share price for BGN : $0.135

ASX company news and announcements for BresaGen Limited (BGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BresaGen Limited (BGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BresaGen Limited (BGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BresaGen Limited (BGN)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Suspension from Official Quotation at close 26/10/06 24 Oct 2006 10:54AM $0.135 $0.135 $0.135 fallen by 0%
- Form 6021 - Notice of compulsory acquisition 19 Oct 2006 3:58PM $0.135 $0.135 $0.135 fallen by 0%
- Extension of Takeover Bid 29 Sep 2006 4:27PM $0.135 $0.135 $0.135 fallen by 0%
- Supplementary Bidder's Statement 22 Sep 2006 4:32PM $0.135 $0.135 $0.135 fallen by 0%
- Extension of Offer Period 15 Sep 2006 4:09PM $0.135 $0.135 $0.135 fallen by 0%
- Preliminary Final Report & Full Year Accounts 8 Sep 2006 6:24PM $0.135 $0.135 $0.135 fallen by 0%
- Hospira Bidder's Statement & BresaGen Targets Statement 24 Aug 2006 4:00PM $0.135 $0.135 $0.135 fallen by 0%
- Target's Statement - Off-market bid by Hospira Holdings 17 Aug 2006 10:50AM n/a $0.135 $0.135 n/a
- Recommended cash takeover offer for BGN by Hospira 11 Aug 2006 10:14AM $0.135 $0.135 $0.135 fallen by 0%
- Reinstatement to Official Quotation 11 Aug 2006 10:14AM $0.135 $0.135 $0.135 fallen by 0%
- Suspension from Official Quotation 8 Aug 2006 9:59AM n/a $0.135 $0.135 n/a
- Trading Halt 4 Aug 2006 12:47PM $0.100 $0.135 $0.135 risen by 35%
- Commitments Test Entity - Fourth Quarter Report 17 Jul 2006 9:30AM $0.092 $0.135 $0.135 risen by 46.74%
- Develops production process for G-CSF 12 Jul 2006 9:42AM $0.095 $0.135 $0.135 risen by 42.11%
- BresaGen attracts overseas process development contract 5 Jul 2006 1:25PM $0.086 $0.135 $0.135 risen by 56.98%
- Commitments Test Entity - Third Quarter Report 24 Apr 2006 10:41AM $0.090 $0.135 $0.135 risen by 50%
- Half Yearly Report & Half Year Accounts 7 Mar 2006 3:17PM $0.090 $0.135 $0.135 risen by 50%
- BresaGen announces distribution agreement for India 3 Feb 2006 10:43AM $0.094 $0.135 $0.135 risen by 43.62%
- Commences 2006 with additional contracts 24 Jan 2006 11:50AM $0.100 $0.135 $0.135 risen by 35%
- Commitments Test Entity - Second Quarter Report 20 Jan 2006 3:46PM $0.100 $0.135 $0.135 risen by 35%
- BresaGen to expand into Mammalian cell derived products 8 Nov 2005 10:02AM $0.105 $0.135 $0.135 risen by 28.57%
- Commitments Test Entity - First Quarter Report 19 Oct 2005 11:43AM $0.084 $0.135 $0.135 risen by 60.71%
- Preliminary Final Report/Full Year Accounts 8 Sep 2005 5:23PM n/a $0.135 $0.135 n/a
- Investment by Paragon Equity Ltd 16 Aug 2005 9:22AM $0.100 $0.135 $0.135 risen by 35%
- Signs Agreement with Middle East Company 8 Aug 2005 10:25AM $0.100 $0.135 $0.135 risen by 35%

1 - 25 of 43 results

Page 1 of 2

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.